Announcement
30 Sep 2025
In September 2025, the United States government announced an agreement with Pfizer to implement most-favored-nation drug pricing for American patients. The agreement secured a three-year reprieve for Pfizer from prospective tariffs on the pharmaceutical industry.
Source
Sign in to access
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 13 Oct 2025
Local operations incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 13 Oct 2025
Tax or social insurance relief
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 13 Oct 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.